The Beginning of the (Merciful) End for VIVUS, Inc Shareholders?

Is this the end for Vivus (NASDAQ: VVUS  ) as a publicly traded company? Investors are left wondering after the Aspen Investment Fund disclosed it had a 9.6% stake of the embattled obesity drug maker, and was contemplating making an offer of $640 million for the entire company.

Shares of Vivus had a rough go, losing more than 80% of their value from 2012 highs as sales of its obesity drug haven't come close to fulfilling blockbuster dreams. Activist investors First Manhattan and Sarissa Capital managed to take over the board and change the CEO, but they haven't been able to change Vivus' fortunes. Will we see a fight between the funds for control of Vivus, or will they use this opportunity to exit what has surely been a losing position for them?

Motley Fool health-care analysts David Williamson and Michael Douglass discuss today's surprising disclosure, what this means for Vivus, and how it could impact its competitors. Watch and find out.

Will this stock be your next multi-bagger?
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer handpicks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year, his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252%, and 1,303% during the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

  


Read/Post Comments (3) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 29, 2014, at 11:19 PM, Vanmusicblues wrote:

    They would be buying Stendra on the cheap

  • Report this Comment On May 30, 2014, at 8:22 AM, marp11 wrote:

    BELVIQ

    a multi blockbuster in the baby step stage

    fools will start the orex pump

    but WS knows...2 generics bad safety

    ARNA when "THEY" let it run

    look out

    shorts are done

  • Report this Comment On May 30, 2014, at 12:48 PM, kazamaza wrote:

    "The Beginning of the (Merciful) End for VIVUS, Inc Shareholders?" articles with heading like the one above are very misleading, to say the least, and are malicious in nature. The author omitted the most basic fact about this company and the fact that it has a rival medicine to that of Viagra and the likes of that class. Its sad some investors read a catchy headline like this one and the next thing you know a very good company is rolling down some hill, at least stock price wise.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2974902, ~/Articles/ArticleHandler.aspx, 9/22/2014 10:24:53 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement